Orthopedics

Your Unread Messages

See All

Your Article Summary

See Latest Articles

Osteonecrosis of the jaw correlated to bisphosphonate therapy in non-oncologic patients: Clinicopathological features of 24 patients
Journal of Rheumatology, 11/09/09

Favia G et al. – ONJ is a harmful side effect of bisphosphonate therapies. Clinicians must be aware of this entity, inform patients of the risks related to dental surgery, and possibly undertake adequate preventive measures.

• Over 4 year period, total of 102 bisphosphonate-treated patients affected by ONJ identified
• 24 patients underwent bisphosphonate therapy for non-neoplastic disease and profile analyzed

• In study cohort, bisphosphonates administered mainly for postmenopausal osteoporosis (20/24 patients, 83.3%)
• Duration of therapy until presentation of ONJ ranging from 11 to 40 months
• Most common triggering event dentoalveolar surgery
• All patients nonsmokers
• 6 manifested multiple ONJ lesions
• 3 had possible comorbidities
• Surgical debridement performed in 19 patients for total of 22 lesions, which were individually considered in followup
• Latter showed complete remission of ONJ in 21/22 lesions

Today in Bone Metabolism...keeping you current

Receive free subspecialty "5-minute updates" via email

Evaluation and management of osteoporosis and fragility fractures in the elderly
Aging Health, 11/23/09

Increased Dickkopf-1 expression accelerates bone cell apoptosis in femoral head osteonecrosis
Bone , 11/23/09

Serum TSH values and risk of vertebral fractures in euthyroid post-menopausal women with low bone mineral density
Bone , 11/20/09

 See all of Bone Metabolism